Representative Publications:

Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994;264:569-71. PubMed link

Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994;79:1157-64. PubMed link

Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ and Cheresh DA. Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression. Nat Med, 2009; 15:1163-1169, PMCID: 2759406. PubMed link

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM and Cheresh DA. A β3 integrin-KRAS-RalB complex drives tumor stemness and resistance to EGFR inhibition. Nature Cell Biol 2014; 16: 457-468, PMCID: 4105198. PubMed link

Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol, 2015;25:234-40. PubMed link

Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott K, Cosset E, Lesperance J, Weis SM, and Cheresh DA. Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discovery, 2017. September 11 2017 DOI:10.1158/2159-8290.CD-17-0539. PubMed link 

Cosset E, Ilmjarv S, Dutoit V, Elliott KC, von Schalscha TL, Camargo MF, Reiss A, Moroshi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dieterich P, Weis SM, Mischel PS and Cheresh DA. Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastomaCancer Cell, 2017; 32(6):856-868. PubMed link

For the current list of Cheresh Lab publications, please click here.